Nattokinase and Stroke Prevention

Every year, about 795,000 Americans have a stroke, and roughly 87% are ischemic — caused by a clot cutting off blood flow to the brain.

That single fact — that most strokes are clotting events — is why a fibrinolytic (clot-dissolving) enzyme like nattokinase keeps surfacing in stroke conversations. But interest is not the same as proof. This article reviews what the research on nattokinase and stroke prevention actually supports, where the evidence stops, and why anyone considering it for stroke risk should involve a doctor first.

Table of Contents

1. Why Most Strokes Are Clotting Events
2. How Nattokinase Could Influence Stroke Risk
3. The Blood Pressure Bridge
4. What the Direct Evidence Does — and Doesn't — Show
5. The Other Side: Bleeding and Hemorrhagic Stroke
6. Where BioAbsorb Nattokinase Fits
7. Frequently Asked Questions
8. Conclusion
9. Research References

1. Why Most Strokes Are Clotting Events

Stroke is the fifth-leading cause of death in the United States, with about 795,000 events and 137,000 deaths each year. The detail that matters for any discussion of nattokinase is the breakdown: roughly 87% of these are ischemic strokes, and only about 13% are hemorrhagic.

An ischemic stroke happens when a clot — or a fragment of fatty plaque that has broken loose — blocks an artery feeding the brain. Because the underlying event is a blockage made largely of fibrin, the same protein that forms clots throughout the body, it is reasonable to ask whether an enzyme that breaks down fibrin could lower the odds of one forming in the first place.

That is the entire premise behind the nattokinase-and-stroke question. It is a mechanistically sensible idea — but as the rest of this article shows, a sensible idea and a proven outcome are two very different things. The CDC's established stroke risk factors — high blood pressure, atherosclerosis, atrial fibrillation, smoking — remain the foundation of real prevention.

2. How Nattokinase Could Influence Stroke Risk

Nattokinase is a fibrinolytic enzyme: it cleaves fibrin directly and supports the body's own clot-clearing machinery. In a double-blind, placebo-controlled crossover study, a single 2,000 FU dose raised D-dimer at 6 and 8 hours and fibrin degradation products at 4 hours in 12 healthy men, while Factor VIII activity fell — direct biochemical evidence that the enzyme nudges the blood toward clot breakdown. Notably, every measured change stayed within the normal physiological range, which is part of why short trials report good tolerability. For a deeper walkthrough of the biochemistry, see our explainer on how nattokinase works.

This fibrinolytic action is the same property explored in the context of nattokinase and blood clots and nattokinase for DVT. In each case the logic is identical: if the enzyme helps clear or limit clots, it might reduce clot-driven events — and an ischemic stroke is, fundamentally, a clot-driven event in the brain.

The honest qualifier is that this is a plausible chain of reasoning, demonstrated on blood markers in small studies, not a measured reduction in actual strokes. A 12-subject pharmacodynamic study tells us the enzyme is biologically active; it does not tell us that taking it lowers a person's lifetime stroke risk. That gap is the central theme of this article.

3. The Blood Pressure Bridge

The strongest indirect link between nattokinase and stroke runs through blood pressure — the single largest modifiable risk factor for stroke. In a randomized, double-blind, placebo-controlled trial of 86 adults with pre- or stage-1 hypertension, 2,000 FU/day for 8 weeks lowered systolic pressure by a net 5.55 mmHg and diastolic by 2.84 mmHg versus control. A 2023 systematic review pooling 6 trials and 546 participants found consistent, if modest, blood-pressure reductions.

Why does a 5 mmHg shift matter? Because the magnitude is clinically meaningful. In an individual-participant analysis of 344,716 people across 48 trials, every 5 mmHg reduction in systolic pressure was associated with about 13% lower stroke risk. That is the most defensible version of a nattokinase stroke-prevention argument: not that the enzyme dissolves a stroke-in-waiting, but that it may lower blood pressure, and lower blood pressure lowers stroke risk.

Even here, restraint is warranted. The blood-pressure trials are small and short, the effect size is on the order of a single lifestyle change, and no study has followed nattokinase users long enough to count strokes. It is a promising signal stacked on a well-established relationship — not a substitute for managing hypertension with a clinician.

4. What the Direct Evidence Does — and Doesn't — Show

The closest thing to direct cardiovascular outcome data is a 12-month study of 1,062 older adults in which 10,800 FU/day reduced carotid plaque size by up to ~36% and lowered carotid intima-media thickness from 1.33 to 1.04 mm. Because carotid plaque is a direct source of the clots and debris that cause ischemic stroke, this is the most stroke-relevant finding in the literature.

But two caveats reshape how that headline should be read. First, the same study found that 3,600 FU/day was ineffective for both plaque and lipids — the benefit appeared only at 10,800 FU/day, which is more than five times the 2,000 FU dose used in most supplements and in the blood-pressure trial above. Second, even this was a measure of plaque on ultrasound, not a count of strokes prevented. A 2018 cardiovascular review summarized the field accurately: nattokinase is a promising fibrinolytic agent whose human outcome data remain limited.

The bottom line is that the evidence supports biological plausibility and surrogate-marker improvements — fibrinolysis, blood pressure, plaque on imaging — but stops short of demonstrating fewer strokes in people. Our complete guide to nattokinase places these benefits in the wider context of what the enzyme can and cannot do.

5. The Other Side: Bleeding and Hemorrhagic Stroke

A clot-dissolving enzyme carries an inherent paradox for stroke: the same action that might help prevent an ischemic stroke can, in the wrong person, contribute to a hemorrhagic one. Drug-information sources document a case of acute cerebellar (bleeding) stroke in a patient with a prior ischemic stroke, and valve thrombosis after a patient replaced warfarin with nattokinase. Roughly 13% of strokes are already hemorrhagic, and adding fibrinolytic and antiplatelet effects in someone with fragile vessels is not a trivial risk.

This is why drug interactions dominate the safety picture. Nattokinase should not be combined with warfarin, heparin, direct oral anticoagulants, or routine aspirin without physician oversight, and it should never be substituted for a prescribed anticoagulant — the people most interested in "natural stroke prevention" are often exactly those already on blood thinners, where the stakes are highest. The trade-offs are covered in depth in our reviews of nattokinase as a natural blood thinner and nattokinase side effects.

For a healthy adult not on blood thinners and without a bleeding disorder, short-term trials at 2,000 FU report no notable adverse effects. The caution is targeted, not blanket — but for a stroke-prevention use case specifically, the bleeding question deserves a real conversation with a doctor, not a footnote.

6. Where BioAbsorb Nattokinase Fits

BioAbsorb Nattokinase Enzyme delivers 100 mg (2,000 FU of fibrinolytic activity) per capsule — the dose used in the human fibrinolysis and blood-pressure studies discussed above. We want to be precise about what that means: 2,000 FU matches the evidence base for fibrinolytic activity and modest blood-pressure support, but it is not the 10,800 FU dose tied to carotid-plaque reduction. We would rather state that plainly than imply a benefit the dose hasn't been shown to deliver.

Where the formulation does add value is delivery and transparency. The enzyme is protected by DRcaps delayed-release veggie capsules, which shield it from stomach acid without the phthalates or plasticizers found in some enteric coatings, releasing it intact in the small intestine. The product is intentionally free of vitamin K2 — relevant because K2 can blunt anticoagulant medications — and is non-GMO, fully vegetarian, and made in a GMP-certified Canadian facility. Every batch is third-party tested for nattokinase activity (≥2,000 FU per capsule), heavy metals, and microbial contaminants.

7. Frequently Asked Questions

Does nattokinase prevent strokes?

No study has shown that it does. Nattokinase has measurable fibrinolytic activity and can lower systolic blood pressure by about 5.5 mmHg, and lower blood pressure is associated with reduced stroke risk — but that is an indirect chain, not direct evidence of fewer strokes. Treat it as a possible complement to proven prevention, never a replacement.

Can I take nattokinase instead of my blood thinner to prevent a stroke?

No, and this is the most important point in the article. A documented case describes valve thrombosis after a patient swapped warfarin for nattokinase. Prescribed anticoagulants are proven to reduce stroke risk in conditions like atrial fibrillation; nattokinase is not a substitute and should only be combined under medical supervision.

What dose was used in the stroke-relevant research?

It depends on the outcome. Blood-pressure and fibrinolysis effects appeared at 2,000 FU/day, while the carotid-plaque benefit required 10,800 FU/day, with 3,600 FU/day proving ineffective. There is no established "stroke prevention dose." See our blood thinner review for how dosing intersects with bleeding risk.

Is nattokinase safe for someone worried about stroke?

For healthy adults not on anticoagulants, short trials at 2,000 FU report no notable adverse effects. The concern is specific: people with bleeding disorders, cerebral microbleeds, recent surgery, or those on blood thinners face real risk, including the rare possibility of a bleeding stroke. A clinician should weigh in before you start.

How long would it take to see any effect?

Fibrinolytic markers shift within hours of a single dose, but blood-pressure changes in the 8-week trial developed over weeks. Any cardiovascular benefit is gradual and modest, and it has not been measured as a reduction in stroke events.

Should nattokinase replace standard stroke prevention?

No. Blood-pressure control, not smoking, managing atrial fibrillation, and prescribed medications remain the evidence-backed foundation. Nattokinase is best understood as a possible adjunct for the right person — discussed with a doctor — not as a standalone strategy.

Conclusion

Nattokinase has a coherent, biologically plausible connection to stroke through fibrinolysis and a modest blood-pressure effect, but the human evidence stops at surrogate markers — and the same clot-dissolving action carries a genuine bleeding caution. If you want to explore a third-party-tested 2,000 FU option as part of a doctor-guided plan, see BioAbsorb Nattokinase Enzyme.

Research References

1. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, Vol. 5, 11601 (2015). A double-blind crossover study in 12 healthy men showing a single 2,000 FU dose significantly elevated fibrinolytic markers (D-dimer, fibrin degradation products) within the normal range.
2. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research, Vol. 31, No. 8 (2008). In 86 adults with pre-/stage-1 hypertension, 2,000 FU/day for 8 weeks reduced systolic pressure by a net 5.55 mmHg and diastolic by 2.84 mmHg.
3. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet, Vol. 397 (2021). Across 344,716 participants, each 5 mmHg systolic reduction was associated with roughly a 13% lower risk of stroke.
4. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: a clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, Vol. 9, 964977 (2022). At 10,800 FU/day for 12 months, carotid plaque size fell by up to ~36% and intima-media thickness from 1.33 to 1.04 mm; 3,600 FU/day was ineffective.
5. Nattokinase supplementation and cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. Reviews in Cardiovascular Medicine, Vol. 24, No. 8 (2023). Pooled analysis of 6 RCTs (546 participants) found significant reductions in systolic and diastolic blood pressure.
6. Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomarker Insights, Vol. 13 (2018). A narrative review concluding nattokinase shows fibrinolytic and anti-atherosclerotic promise while noting that human outcome data remain limited.
7. Stroke: Condition Information. National Institutes of Health — Eunice Kennedy Shriver National Institute of Child Health and Human Development (2025). Reports ~795,000 US strokes annually, ~137,000 deaths, and that ~87% of strokes are ischemic.
8. Nattokinase. Drugs.com Natural Products Database (2026). Clinical monograph documenting bleeding-risk cautions, a reported cerebellar hemorrhage case, and valve thrombosis after substitution for warfarin.
9. Ischemic Stroke. Yale Medicine — Conditions (accessed June 2026). Overview of ischemic stroke, describing how a clot or a dislodged fragment of fatty plaque blocks an artery supplying the brain, and that ischemic strokes account for the large majority of all strokes.
10. Stroke Facts. Centers for Disease Control and Prevention (accessed June 2026). US stroke statistics and established modifiable risk factors, including high blood pressure, atherosclerosis, atrial fibrillation, and smoking.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.